Stocks making the biggest moves premarket: Intel, SpaceX, Micron, Carnival & more

Premarket trading was led by Intel, which surged nearly 9% after Trump said it reached a U.S. chip deal with Apple; Apple rose less than 1%, while Marvell gained nearly 7% and Lam Research and Applied Materials rose about 5%. Accenture tumbled 13% after announcing a $4.175 billion acquisition package, while Pfizer fell 1% on its CFO transition and Smith & Wesson jumped 14% after an earnings and revenue beat. Cruise and airline names also firmed, with Carnival up 3% and United, Delta and American Airlines all rising about 2%.

Analysis

The key read-through is that this is less a single-stock catalyst and more a policy-backed reshoring signal for the semiconductor value chain. If Intel is being framed as a domestic foundry beneficiary, the market will start paying a higher multiple for U.S.-capex intensity and a lower one for names whose growth still depends on Asia-linked packaging, assembly, or export demand. That creates a relative-value setup where equipment and memory can continue to catch a sympathy bid for a few sessions, but the cleaner medium-term expression is in companies that gain from incremental U.S. fab buildout rather than just headline semiconductor beta.

The second-order winner is likely the capex ecosystem, but the timeline matters: foundry localization takes years, not quarters, so the near-term move is sentiment-driven while the earnings impact is back-half 2026 and beyond. In contrast, the biggest loser is the consulting/advisory complex when M&A is viewed as balance-sheet drag rather than strategic optionality; a large acquisition package in a weakening demand environment often gets punished because investors fear integration risk plus delayed synergy realization. That type of reaction is usually most severe over 1-3 trading days and can mean-revert if the target assets are obviously high quality.

Within travel, lower fuel remains a cleaner fundamental tailwind than the market typically prices in on day one. Airlines and cruise operators should outperform if oil stays weak for more than a week, but the better trade is the higher operating leverage names where a modest input-cost decline flows more directly into margin expansion. Healthcare looks idiosyncratic: the CFO change at a defensive large cap is not a thesis breaker, but it can cap multiple expansion if the market reads it as a prelude to guidance conservatism or capital allocation drift.

Key Decisions for Investors

• Long INTC vs short a basket of high-beta semiconductor names for 1-3 weeks; use the policy narrative as a relative-value catalyst, not a directional chip bet. Risk/reward improves if the market keeps pricing domestic manufacturing optionality into Intel while the broader group gives back sympathy gains.
• Fade the broad chip sympathy move after the first day: short MRVL or an equal-weight semiconductor basket against INTC if the rally extends into the close. This targets the overreaction risk where only a subset of the supply chain actually benefits over a 12-24 month horizon.
• Buy 1-2 month call spreads in LRCX or AMAT on any intraday dip; these are the cleanest second-order beneficiaries of incremental U.S. fab capex, with better earnings sensitivity than chip designers. Keep size modest because the move is policy-led and can retrace quickly.
• Sell downside in ACN only if you believe the market is over-penalizing execution risk; otherwise avoid catching the falling knife for now. The better expression is to wait 2-3 sessions for stabilization before considering a small tactical long, since integration concerns can create a longer de-rating window.
• Long UAL/DAL vs short crude-sensitive consumer discretionary for a 2-4 week window if oil weakness persists. The trade has favorable asymmetry because fuel relief hits airline P&L faster than the market typically models, while downside is limited if energy reverses only modestly.